• 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • Deferoxamine br Curran Jr WJ Paulus


    [2] Curran Jr WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452–60. [3] St James S, Grassberger C, Lu HM. Considerations when treating lung cancer with passive scatter or active scanning Deferoxamine therapy. Transl Lung Cancer Res 2018;7:210–5.
    [4] Chang JY, Zhang X, Knopf A, Li H, Mori S, Dong L, et al. Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG thoracic and lymphoma subcommittee. Int J Radiat Oncol Biol Phys 2017;99:41–50.
    [5] Chang JY, Li H, Zhu XR, Liao Z, Zhao L, Liu A, et al. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys 2014;90:809–18. [6] Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Liao Z, et al. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol 2018;8:58–65.
    [9] Liu W, Zhang X, Li Y, Mohan R. Robust optimization of intensity modulated
    [10] Cao W, Lim G, Li X, Li Y, Zhu XR, Zhang X. Incorporating deliverable monitor unit constraints into spot intensity optimization in intensity-modulated proton therapy treatment planning. Phys Med Biol 2013;58:5113–25. [11] Li Y, Niemela P, Liao L, Jiang S, Li H, Poenisch F, et al. Selective robust optimization: a new intensity-modulated proton therapy optimization strategy. Med Phys 2015;42:4840–7. [12] Zhang X, Li X, Quan EM, Pan X, Li Y. A methodology for automatic intensity-modulated radiation treatment planning for lung cancer. Phys Med Biol 2011;56:3873–93.
    [15] Li H, Zhu XR, Zhang X. Reducing dose uncertainty for spot-scanning proton beam therapy of moving tumors by optimizing the spot delivery sequence. Int J Radiat Oncol Biol Phys 2015;93:547–56. [16] Stata. Release 15 ed. College Station, TX: StataCorp LP; 2017. p. Statistical Software.
    [17] Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol 2015;115:367–72. [18] Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: final results of a phase 2 study. JAMA Oncol 2017;3: e172032.
    [19] Liao Z, Lee JJ, Komaki R, Gomez DR, O’Reilly MS, Fossella FV, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol 2018;36:1813–22. [20] Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 2010;77:357–66.
    [21] Haque W, Verma V, Fakhreddine M, Butler EB, Teh BS, Simone 2nd CB. Trends in cardiac mortality in patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2018;100:470–7.
    142 Outcomes after IMPT for NSCLC
    [22] Wang K, Pearlstein KA, Patchett ND, Deal AM, Mavroidis P, Jensen BC, et al. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiother Oncol 2017;125:293–300.
    [23] Yegya-Raman N, Wang K, Kim S, Reyhan M, Deek MP, Sayan M, et al. Dosimetric predictors of symptomatic cardiac events after conventional-dose chemoradiation therapy for inoperable NSCLC. J Thorac Oncol 2018;13:1508–18.